Analytics, News, and Forecasts for CFD Markets: stock news — 27-03-2017.

The main US stock indexes ended the auction mixed in the background of Friday's failure to vote in the US Congress on President Donald Trump's bill on health care reform, which made investors doubt that he will be able to carry out tax reform.

In addition, as shown by data provided by the Federal Reserve Bank of Dallas, business activity of Texas producers deteriorated significantly in March, recording the first drop in the last 7 months. In addition, the March value was lower than the experts' forecasts. According to the report, the manufacturing index of the Federal Reserve Bank of Dallas in March fell to 16.9 points from 24.5 points in February. Experts expected that the index will drop only to 22.0 points.

The cost of oil moderately declined on Monday amid uncertainty over whether OPEC will extend the agreement to cut production for the second half of the year. Pressure on oil also provided data from the company Baker Hughes. On Friday, Baker Hughes reported that from 18 to 24 March the number of active drilling rigs for oil production in the US increased to 652 units from 631 units. The latter value is the highest since mid-September 2015.

The components of the DOW index have mostly grown (18 out of 30). The shares of Chevron Corporation fell more than others (CVX, -1.52%). The leader of growth was the shares of E. I. du Pont de Nemours and Company (DD, + 1.28%).

Most sectors of the S & P index recorded an increase. The financial sector fell most of all (-0.2%). The leader of growth was the healthcare sector (+ 0.7%).

At closing:

DJIA -0.22% 20.550.66 -46.06

Nasdaq + 0.20% 5,840.37 +11.63

S & P -0.10% 2,341.61 -2.37

Major U.S. stock-indexes little changed on Monday as investors picked up beaten-down stocks after Wall Street tumbled following the withdrawal of President Donald Trump's healthcare reform bill. Wall Street has rallied since November on bets that Trump's campaign promises of tax cuts and deregulation would sail through a Congress controlled by Republicans.

Most of Dow stocks in negative area (17 of 30). Top loser - Chevron Corporation (CVX-1.31%). Top gainer - E. I. du Pont de Nemours and Company (DD, +1.23%).

Most of S&P sectors also in negative area. Top loser - Industrial goods (-0.5%). Top gainer - Healthcare (+0.6%).

At the moment:

Dow 20501.00 -74.00 -0.36%

S&P 500 2337.25 -7.50 -0.32%

Nasdaq 100 5377.25 -1.50 -0.03%

Oil 47.71 -0.26 -0.54%

Gold 1254.20 +5.70 +0.46%

U.S. 10yr 2.37 -0.03

U.S. stock-index futures fell, as the failure of President Donald Trump's healthcare reform bill cast doubts over his ability to deliver on his agenda of tax cuts and simpler regulations.

Global Stocks:

Nikkei 18,985.59 -276.94 -1.44%

Hang Seng 24,193.70 -164.57 -0.68%

Shanghai 3,266.82 -2.62 -0.08%

FTSE 7,275.22 -61.60 -0.84%

CAC 4,998.29 -22.61 -0.45%

DAX 11,951.59 -112.68 -0.93%

Crude $47.50 (-0.98%)

Gold $1,257.60 (+0.73%)

(company / ticker / price / change ($/%) / volume)

Upgrades:

Downgrades:

Other:

Starbucks (SBUX) initiated with a Outperform at Telsey Advisory Group; target $66

Stocks in Europe have been falling four out of the five trading days this week, as traders have looked to the U.S. where President Donald Trump has been struggling to push through his promised repeal of Obama's Affordable Care Act. The vote was scheduled for Thursday, but pushed back a day because of opposition from some Republicans. Right before the European market closed on Friday House Speaker Paul Ryan went to the White House to meet with Trump, which was being interpreted by some as a bad sign for the passage of the bill.

Earnings in China's industrial sector surged 31.5% in the January to February period from a year earlier, supported by an acceleration in output and higher commodities prices, official data showed Monday. Apart from rapid growth in coal, steel and oil prices, lower costs for the companies' main businesses also contributed to stronger profits, National Bureau of Statistics economist He Ping said in a statement accompanying the data release.